文献速递炎症性肠病

538例炎症性肠病患者首剂抗TNF治疗长期持续性的20年真实世界研究

Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study.
PubMed 文献 · Aliment Pharmacol Ther · 2021-06-20

该单中心回顾性研究纳入538例炎症性肠病患者,评估首剂抗TNF治疗的持续性及影响因素。中位随访8.1年,总队列中位治疗持续性为2.3年,近半数患者2年内停药。治疗失败和副作用是停药主因,女性是UC治疗失败的独立预测因素。

要点

  • 首剂抗TNF治疗中位持续性仅2.3年,近半数患者2年内停药。
  • CD患者治疗持续性长于UC(39 vs 13个月),CD中用阿达木单抗长于英夫利西单抗。
  • 治疗失败(52%)和副作用(25%)是停药最常见原因,女性是UC治疗失败的独立预测因素。

核心结论

  • 炎症性肠病患者首剂抗TNF治疗的长期持续性有限,主要因治疗失败和副作用停药。

研究设计与样本

  • 单中心回顾性研究,来自过去20年接受抗TNF治疗的538例炎症性肠病患者注册资料。
  • 采用Kaplan-Meier分析和log-rank检验描述治疗持续性,多变量Cox回归分析治疗失败危险因素。

主要发现

  • 总队列中位随访8.1年,中位治疗持续性为2.3年(28个月,95%CI 22-38),近半数患者2年内停药。
  • 男性治疗时间长于女性(37 vs 23个月,P=0.002)。
  • CD治疗持续性长于UC(39 vs 13个月,P<0.001),CD中阿达木单抗长于英夫利西单抗(67 vs 19个月,P<0.001)。
  • 停药原因:治疗失败52%、副作用25%、缓解14%。
  • 女性是UC治疗失败的独立预测因素(HR 1.73,95%CI 1.02-2.92,P=0.04)。

临床怎么用

  • 临床应预期首剂抗TNF治疗持续性有限,需早期评估疗效和副作用,及时调整方案。
  • 对UC女性患者应关注治疗失败风险,加强监测和随访。

局限性

  • 单中心回顾性研究,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anti-TNF antibodies were the first biologic treatment option for patients with inflammatory bowel diseases. AIMS: To assess length of treatment persistence of first anti-TNF therapy and influencing factors used in the standard care of patients with inflammatory bowel diseases. METHODS: Single-centre, retrospective study from a register including patients who received anti-TNF therapy in the last 20 years at the study centre. Kaplan-Meier analysis with log-rank test was used to describe treatment persistence. With multivariable Cox regression analysis, risk factors for treatment failure were investigated. RESULTS: Five hundred thirty-eight patients (CD, Crohn's disease: 367, UC, ulcerative colitis: 147, inflammatory bowel disease unclassified: 24) with a median follow-up of 8.1 years were included. Median (95% confidence interval) treatment persistence in the total cohort was 2.3 years (28 [22, 38] months), and nearly half of patients withdrew from treatment within 2 years. Male patients were treated longer than females (male: 37 [25, 48] months, female: 23 [14, 33] months, P = 0.002). Treatment persistence was longer in CD compared to UC (CD: 39 [30, 50] months, UC: 13 [9, 19] months, P < 0.001), and patients with CD remained longer on adalimumab than on infliximab treatment (adalimumab: 67 [55, 95] months, infliximab: 19 [14, 31] months, P < 0.001). Treatment failure (52%) and side effects (25%) were the most common reasons for withdrawal from therapy; 14% withdrew due to remission. Female sex was identified as independent predictor for treatment failure in UC (hazard ratio [CI]: 1.73 [1.02-2.92], P = 0.04). CONCLUSION: Long-term treatment persistence of first anti-TNF therapy was limited in patients with inflammatory bowel diseases, primarily due to treatment failure and side effects.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Blesl A, Binder L, Högenauer C, et al. Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study. Aliment Pharmacol Ther. 2021. PMID: 34151449. doi:10.1111/apt.16478

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。